Product logins

Find logins to all Clarivate products below.


Binge Eating Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Binge Eating Disorder (US)

Binge eating disorder (BED) is a prevalent condition in the United States; it affects millions of individuals across diverse demographics. BED is characterized by recurrent episodes of excessive food consumption, leading to significant emotional and physical distress. Effective treatment often involves a combination of psychotherapy (e.g., cognitive behavioral therapy [CBT]) and medications such as lisdexamfetamine and antidepressants. However, BED remains underdiagnosed due to stigma and low awareness. Addressing these challenges through public education and healthcare training can improve diagnosis and treatment outcomes, while ongoing research may lead to more-effective therapies. In this report, we assess drug usage patterns in BED based on U.S. patient-level claims data.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed BED patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed BED patients?
  • How has lisdexamfetamine (Vyvanse, generics) been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of BED patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of BED patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Key drugs covered

bupropion, lisdexamfetamine (Vyvanse; generics), semaglutide, SSRIs, topiramate

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Key features

Dashboard featuring interactive visuals, easy navigation, and expanded analyses.

Real-world data

Longitudinal patient-level claims data analysis

Key analyses

  • Brand / therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flow charts

Related Market Assessment Reports

Report
Immune Thrombocytopenic Purpura – Unmet Need – Unmet Need – Immune Thrombocytopenic Purpura (US/EU)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder marked by increased platelet destruction and impaired megakaryocyte production. Bleeding ranges from petechiae to lifethreatening…
Report
Chronic Urticaria – Unmet Need – Unmet Need – Chronic Urticaria (US/EU)
Treatment of CSU and CIndU is dominated by oral medications, including approved therapies such as first- and second-generation antihistamines and a range of off-label options (e.g.,…
Report
Rheumatoid Arthritis – Unmet Need – Unmet Need – TNFi-Refractory Rheumatoid Arthritis (US/EU)
Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor (TNF)-alpha inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb’s…
Report
Neuromyelitis Optica Spectrum Disorder (NMOSD) – Current Treatment – Current Treatment: Physician Insights – Neuromyelitis Optica Spectrum Disorder (US)
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic autoimmune neuroinflammatory disorder marked by optic neuritis and longitudinally extensive transverse myelitis, often leading to…
Report
Ovarian Cancer – Unmet Need – Unmet Need – Recurrent Platinum-Resistant Ovarian Cancer (US EU)
The treatment landscape for advanced platinumresistant ovarian cancer remains highly challenging, as conventional singleagent chemotherapies provide limited and shortlived benefit. Unlike the…